Hematologic Neoplasms

"Hematologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Descriptor ID	D019337
MeSH Number(s)	C04.588.448 C15.378.400
Concept/Terms	Hematologic Neoplasms Hematologic Neoplasms Hematologic Malignancy Neoplasms, Hematologic Hematologic Neoplasm Neoplasm, Hematologic Hematological Neoplasms Hematological Neoplasm Neoplasm, Hematological Neoplasms, Hematological Malignancies, Hematologic Malignancy, Hematologic Hematologic Malignancies Hematological Malignancies Hematological Malignancy Malignancies, Hematological Malignancy, Hematological Hematopoietic Neoplasms Hematopoietic Neoplasms Neoplasms, Hematopoietic Hematopoietic Neoplasm Neoplasm, Hematopoietic Hematopoietic Malignancies Hematopoietic Malignancy Malignancies, Hematopoietic Malignancy, Hematopoietic

Below are MeSH descriptors whose meaning is more general than "Hematologic Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Hematologic Neoplasms".

Hematologic Neoplasms
Bone Marrow Neoplasms

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hematologic Neoplasms" by people in this website by year, and whether "Hematologic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 95 publications over 28 distinct years, with a maximum of 12 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	0	1	1
2000	1	1	2
2001	0	2	2
2002	1	0	1
2003	1	0	1
2004	1	0	1
2005	2	3	5
2006	0	2	2
2007	5	0	5
2008	1	1	2
2009	1	1	2
2010	2	0	2
2011	1	0	1
2012	4	0	4
2013	2	2	4
2014	2	1	3
2015	7	0	7
2016	3	0	3
2017	5	0	5
2018	2	1	3
2019	6	1	7
2020	5	0	5
2021	1	1	2
2022	4	0	4
2023	12	0	12
2024	6	0	6
2025	1	0	1

Below are the most recent publications written about "Hematologic Neoplasms" by people in Profiles.

Doolub G, Raichman A, Abramov D, Bang V, Parwani P, Karunanithi K, Abdel-Qadir H, Kobo O, Mamas MA. Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective. Expert Rev Cardiovasc Ther. 2025 Jan-Feb; 23(1-2):35-43.

View in: PubMed
Guido O, Lubwama M, Kiconco P, Okeng A, Najjingo I, Aboce E, Phiona R, Nabbanja H, Ndagire M, Eva K, Enock W, Orem J, Joloba ML, Bwanga F. Human cytomegalovirus infection among febrile hematological cancer patients at the Uganda Cancer Institute. Microbiol Spectr. 2024 Nov 05; 12(11):e0048124.

View in: PubMed
Bi X, Grosso D, Gradone A, Filicko-O'Hara J, McCorkell KA, O'Hara W, Wagner JL, Flomenberg N, Gergis U. A Tender Reduced-Intensity Conditioning for the Unfit: A Novel 4 Gy Total Body Irradiation-Based Conditioning Followed by Two-Step Haploidentical Stem Cell Transplant, Results of a Prospective Trial. Transplant Cell Ther. 2024 10; 30(10):1009.e1-1009.e11.

View in: PubMed
Saeidi V, Jackson Cullison SR, Doudican NA, Carucci JA, Stevenson ML. CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary Cutaneous Squamous Cell Carcinoma and Hematologic Malignancy. Dermatol Surg. 2024 12 01; 50(12):1096-1101.

View in: PubMed
Maziarz RT, Gergis U, Edwards ML, Song Y, Liu Q, Anderson A, Signorovitch J, Manghani R, Simantov R, Shin H, Sivaraman S. Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective. Blood Adv. 2024 03 12; 8(5):1200-1208.

View in: PubMed
Khera N, Edwards ML, Song Y, Sun R, Manghani R, Shin H, Simantov R, Signorovitch J, Sivaraman S, Gergis U. Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies. Adv Ther. 2024 Apr; 41(4):1637-1651.

View in: PubMed
Binder AF, Hossain A, Doshi R, Vivero A, Gonzalez KM, Gentsch A, Wilde L, Rising KL. Patient and caregiver perceptions of the possibility of home blood transfusions. Transfusion. 2024 03; 64(3):483-492.

View in: PubMed
Sahin Y, Wang YL, Pei J, Mansoor N, Styler M, Testa JR, Nejati R. Multiple Genomic Alterations, Including a Novel AFF4::IRF1 Fusion Gene, in a Treatment-Refractory Blastic Plasmacytoid Dendritic-Cell Neoplasm: A Case Report and Literature Review. Int J Mol Sci. 2023 Dec 25; 25(1).

View in: PubMed
Ajabnoor AM, Parisi R, Zghebi SS, Ashcroft DM, Faivre-Finn C, Morris C, Mamas MA, Kontopantelis E. Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019. Cancer. 2024 04 15; 130(8):1316-1329.

View in: PubMed
Yong JH, Mai AS, Matetic A, Elbadawi A, Elgendy IY, Lopez-Fernandez T, Mamas MA. Cardiovascular Risk in Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis. Am J Cardiol. 2024 02 01; 212:80-102.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement